Synthetic Triterpenoid Administration Avoiding CYP3A4 Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need to understand and minimize drug-drug interactions between synthetic triterpenoids and CYP3A4 modulators, as these interactions can alter the plasma concentrations and therapeutic effects of synthetic triterpenoids like bardoxolone methyl and omaveloxolone, leading to potential side effects and reduced efficacy.
Innovation Solution
The methods involve determining if a patient is being administered a CYP3A4 modulator and selecting or administering a therapeutically effective amount of a compound, such as bardoxolone methyl or omaveloxolone, while avoiding concomitant use of CYP3A4 modulators to minimize adverse interactions and maximize pharmacological effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic triterpenoids are administered to patients, then therapeutic effects are achieved, but drug-drug interactions with CYP3A4 modulators can alter plasma concentrations and cause side effects
Solution Approach 1:
The patent applies preliminary action by requiring healthcare providers to assess and document CYP3A4 modulator use before initiating synthetic triterpenoid therapy. This advance assessment allows for proactive identification of potential drug interactions and prevents adverse effects before they occur, rather than reacting after problems arise.
Solution Approach 2:
The patent implements feedback mechanisms through monitoring plasma concentrations of synthetic triterpenoids and adjusting dosing based on these measurements. The system continuously monitors for drug interactions and modifies treatment parameters accordingly, creating a closed-loop approach that maintains therapeutic efficacy while minimizing adverse effects.
2Adaptability or versatility
If CYP3A4 modulators are used concomitantly with synthetic triterpenoids, then additional therapeutic benefits may be achieved, but plasma concentrations of synthetic triterpenoids can be altered leading to reduced efficacy or increased side effects
Solution Approach 1:
The patent applies dynamics by implementing flexible dosing adjustments based on individual patient responses and plasma concentration monitoring. Rather than using fixed dosing, the system dynamically adapts the synthetic triterpenoid dose according to measured plasma levels and clinical response, allowing for optimization when combined with CYP3A4 modulators while maintaining stability.
Solution Approach 2:
The patent utilizes parameter changes by monitoring and adjusting plasma concentration parameters of synthetic triterpenoids when CYP3A4 modulators are present. The system changes dosing parameters, monitoring intervals, and therapeutic targets based on observed plasma levels, enabling safe and effective combination therapy through controlled parameter modification.
3Object-affected harmful factors
If monitoring and assessment procedures for CYP3A4 modulator interactions are implemented, then adverse interactions can be avoided, but treatment complexity and time required for assessment increase
Solution Approach 1:
The patent applies universality by creating a multi-functional assessment framework that serves multiple purposes: identifying CYP3A4 modulator use, assessing interaction risk, determining dosing adjustments, and monitoring plasma concentrations. This integrated approach consolidates multiple functions into a single coordinated process, reducing overall complexity while maintaining comprehensive safety monitoring.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach helps in avoiding adverse drug interactions, ensuring effective treatment by maintaining optimal plasma concentrations of synthetic triterpenoids and reducing side effects, thereby enhancing their therapeutic benefits.
Implementation Method 1
The cytochrome P450 enzyme system (CYP450) is responsible for the biotransformation of drugs from active substances to inactive metabolites that can be excreted from the body
Implementation Method 2
There is a significant, unmet need for understanding whether modulators of CYP3A4 affect plasma concentrations of synthetic triterpenoids
Data Source
AI summary
Provided are methods of administering synthetic tri terpenoids, such as bardoxolone methyl or omaveloxolone, to a patient in need thereof while avoiding adverse drug interactions with cytochrome P450 3A4 (CYP3A4) modulators. Such treatment methods comprise avoiding, contraindicating, or discontinuing concomitant use or co-administration of a cytochrome P450 3A4 modulator.